Nasdaq

New Study Validates the Signatera® MRD Test and Demonstrates its Clinical Utility in Early-Stage Esophageal Cancer

AUSTIN, Texas, July 28, 2021 /PRNewswire/ -- Natera,Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced a new peer-reviewed paper published in Gastroenterology ...
Yahoo Finance

Natera’s Signatera test to be used in Phase III bladder cancer trial

US-based clinical genetic testing company Natera said that its Signatera test will be utilised in the newly activated ARCHER trial, a Phase III study sponsored by NRG Oncology. The trial focuses on ...
Nasdaq

FDA Grants Breakthrough Device Designation to Natera's Signatera Test

SAN CARLOS, Calif., May 6, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA) today announced that the U.S. Food and Drug Administration (FDA) has granted "Breakthrough Device" designation for its ...
Business Insider

Medicare Issues Positive Draft Local Coverage Determination for Natera's Signatera™ MRD Test in Colorectal Cancer

SAN CARLOS, Calif., Aug. 22, 2019/PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that the Palmetto MolDX program has proposed a local coverage ...
Seeking Alpha

Natera: Focus On Signatera And H1 2024 Results

Natera, Inc. is a diagnostic company focusing on cfDNA tests in women's health, organ health, and oncology. Natera's MRD test, Signatera, demonstrated strong growth, with a 64% increase in processed ...
Morningstar

Signatera™ Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of a new study in the Journal of Clinical Oncology Precision Oncology (JCO PO), ...
Business Insider

New Signatera™ Data in Multiple Myeloma, Colorectal Cancer and Ovarian Cancer Highlights Clinical Utility of MRD in Real-World Settings

AUSTIN, Texas, May 26, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new clinical data on its personalized and ...
Business Wire

Signatera™ Test Selected for NRG-Sponsored Phase III ARCHER Trial in Bladder Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the activation of the NRG Oncology trial, ARCHER (NRG-GU015), a ...
Morningstar

Phase III PALLAS Study Shows Signatera™ MRD Testing Provides Powerful Post‑Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2‑ Breast Cancer

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, together with Alliance Foundation Trials, LLC (AFT) and the Austrian Breast and Colorectal Cancer Study Group ...
Business Wire

Medicare Extends Coverage of Natera’s Signatera™ MRD Test to Breast Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it has received written confirmation from the Centers for Medicare & ...
Zacks Investment Research on MSN

Natera files Signatera CDx PMA with FDA for bladder cancer MRD test

Natera NTRA recently announced the submission of a premarket approval (PMA) application to the FDA for its Signatera CDx test, a personalized molecular residual disease (MRD) assay for patients with ...